Search Within

Gary Schwartz

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (6)
Groups
  1. Advanced Practice Providers (18)
  2. Nursing (17)
  3. Department of Medicine (15)
  4. Solid Tumor Oncology Division (15)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Richard Carvajal (13)
  2. Heather Dials (9)
  3. Mark Dickson (8)
  4. Paul Chapman (6)
  5. Jedd Wolchok (5)
  6. Lauren Cane (5)

More People

Years
  1. 2016 (1)
  2. 2013 (1)
  3. 2012 (2)
  4. 2011 (2)
  5. 2010 (5)
  6. 2009 (2)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Clinical Cancer Research (3)
  3. Blood (1)
  4. Cancer Chemotherapy and Pharmacology (1)
  5. Investigational New Drugs (1)
  6. JAMA - Journal of the American Medical Association (1)
Publishers
  1. American Society of Clinical Oncology (11)
  2. American Association for Cancer Research (3)
  3. Springer (2)
  4. American Medical Association (1)
  5. American Society of Hematology (1)

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Journal Article

    Dickson, M. A.; Shah, M. A.; Rathkopf, D.; Tse, A.; Carvajal, R. D.; Wu, N.; Lefkowitz, R. A.; Gonen, M.; Cane, L. M.; Dials, H. J.; more...
    Cancer Chemotherapy and Pharmacology (2010)

    Fulltext@MSK | Save
  • A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
    Meeting Abstract

    Schwartz, G. K.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D.; Shannon, P.; Gordon, M.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol
    Meeting Abstract

    Dickson, M. A.; Carvajal, R. D.; Shah, M.; Tse, A. N.; Dials, H.; Cane, L. M.; Schwartz, G. K.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase I study of FOLFOX administered with flavopiridol (F) in patients with refractory solid tumors
    Meeting Abstract

    Dickson, M. A.; Carvajal, R. D.; Shah, M. A.; Cane, L. M.; Dials, H. J.; Schwartz, G. K.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
    Journal Article

    Tse, A. N.; Klimstra, D. S.; Gonen, M.; Shah, M.; Sheikh, T.; Sikorski, R.; Carvajal, R.; Mui, J.; Tipian, C.; O'reilly, E.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
    Meeting Abstract

    O'Dwyer, P. J.; LoRusso, P.; DeMichele, A.; Gupta, V.; Barbi, A.; Dials, H.; Chen, I.; Courtney, R.; Wilner, K.; Schwartz, G. K.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Pharmacokinetics (PK) of split-dose flavopiridol (F) administered with CPT-11 (CPT) and cisplatin (Cis)
    Meeting Abstract

    Carvajal, R. D.; Tse, A.; Wu, N.; Gonen, M.; Lefkowitz, R.; Dials, H.; Barbi, A.; Mui, J.; Schwartz, G. K.; Shah, M.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks
    Journal Article

    Sharma, S.; Kemeny, N.; Schwartz, G. K.; Kelsen, D.; O'reilly, E.; Ilson, D.; Coyle, J.; De Jager, R. L.; Ducharme, M. P.; Kleban, S.; more...
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save